Hashtag
Men's Weekly

Merck Announces Emerging Biotech Grant Program Winners

  • Award recipients to receive in-kind technologies and services to accelerate therapeutics to market
  • Merck experts to provide consultation and training in qualification, risk assessment, and process optimization
  • Program extended this year to Australia, New Zealand, Taiwan, South Korea

SINGAPORE - Media OutReach Newswire - 1 November 2024 - Merck, a leading science and technology company, today announced the winners of its Emerging Biotech (EB) Grant Program in Asia Pacific.

The Award is designed to support biotech startups with resources to enable emerging companies to discover, develop, optimize, and commercialize therapeutics faster and more efficiently.

Merck Emerging Biotech Award Recipients for Taiwan receiving their awards at the award ceremony.
Merck Emerging Biotech Award Recipients for Taiwan receiving their awards at the award ceremony.
Merck Emerging Biotech Award Recipients for Australia receiving their awards at the award ceremony.
Merck Emerging Biotech Award Recipients for Australia receiving their awards at the award ceremony.



"Merck is committed to supporting exceptional biotech companies to both kickstart and streamline their journey from discovery to manufacturing with our grant program," said Chua Keng Hock, Senior Vice President, Process Solutions Asia Pacific, Life Science business of Merck. "We recognize the complexities involved in delivering next-generation therapies to the market. Merck's EB Grant is designed to expedite the development of treatments that address critical unmet medical needs."

The award recipients are:

Country
Grand Prize Winner
Finalist Prize Winners
Special Mention
Australia & New Zealand
Southern RNA for enabling the manufacturing of mRNA for personalized medicines
Institute for Drug Technology for enabling the manufacturing of antibody-drug conjugates.

Psaio for developing bispecific antibodies targeting prostate-specific antigen to treat prostate cancer.
Kimer Med for developing

a family of broad-spectrum antiviral biologics to treat infectious diseases, and for pandemic protection.
Taiwan
HanchorBio for developing clinical-stage and next-generation immuno-oncology therapies through innovation in cutting-edge designer biologics with novel, multi-functional modalities.
Pell Biomed Technology for developing more efficient and cost-effective gene-modified cell therapies.

Glyconex for glycan-directed cancer therapies including antibody-drug conjugates to treat a range of solid tumors such as gastrointestinal cancers.
Shine-On BioMedical for developing targeted exosomes as a platform for drug delivery as well as tri-specific antibody for cancer treatment.

Merck experts selected the winning submissions based on the scientific and societal merit of the therapy in development and process challenges and expertise gaps that may impact ongoing development. In-kind technologies and services from Merck will be awarded to the winners in Australia & New Zealand and Taiwan to help solve these challenges.

Merck first started the EB grant program in 2014 in the United States and has expanded its reach to include Europe, China, South Korea and Taiwan in recent years. In 2024, the EB Grant was extended to Australia & New Zealand and is open to Taiwan and South Korea (the winners for South Korea were announced in July 2024). To-date, Merck's EB Grant program has awarded technologies and consultation to over 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders.

https://www.sigmaaldrich.com/SG/en/applications/pharmaceutical-and-biopharmaceutical-manufacturing/biotech-resource-hub/startup-programs#our-grant-programs

Other Merck grants at group level:
https://www.merckgroup.com/en/research/open-innovation.html

Hashtag: #Merck

The issuer is solely responsible for the content of this announcement.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.

Business News

Highbrow Unveils Its New Beauty Salon at The Adelphi

SINGAPORE - Media OutReach Newswire - 27 June 2025 - HighBrow, one of Singapore’s most trusted names in brow, lash, and nail care, is thrilled to announce the launch of its new beauty salon at The Ad...

Hashtag.net.au - avatar Hashtag.net.au

Cyberport 5 as Hong Kong's New I&T Landmark

Driving Emerging Strategic Industries Development Heralding a New Chapter in Integration of I&T and the Community HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - The Cyberport 5 b...

Hashtag.net.au - avatar Hashtag.net.au

VinFast signs dealer financing cooperation agreement with BCA

JAKARTA, INDONESIA - Media OutReach Newswire - 27 June 2025 - VinFast has officially entered into a pivotal financial partnership with PT Bank Central Asia Tbk. (BCA), one of Indonesia's leading priv...

Hashtag.net.au - avatar Hashtag.net.au

Food Expo PRO and Hong Kong International Tea Fair Return in August with New Coffee Zone and Expanded Halal Sector

HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo PRO and Hong Kong International Tea Fair will be staged concurrent...

Hashtag.net.au - avatar Hashtag.net.au

Food Expo PRO and Hong Kong International Tea Fair: One-Stop F&B Platform Returns in August

Spotlighting Food Science & Tech HONG KONG SAR - Media OutReach Newswire - 27 June 2025 - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo PRO and Hong Kong Internation...

Hashtag.net.au - avatar Hashtag.net.au

The best CFD broker 2025': Octa receives yet another award

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 27 June 2025 - Octa, a globally regulated and trusted broker since 2011, was recently named 'The best CFD broker 2025' by the AllForexRating.com po...

Hashtag.net.au - avatar Hashtag.net.au

Health & Wellness

Telehealth Could be the Catalyst for Better Heart Health in Australia

Hashtag.net.au - avatar Hashtag.net.au

Image by stockking on Freepik Heart disease is one of the leading causes of death in Australia despite decades of advancements in medicine and health education campaigns. More than 400 Australians ...

Disability Care in Melbourne: What Families Need to Know in 2025

Hashtag.net.au - avatar Hashtag.net.au

If you’re supporting a loved one with a disability in Melbourne, you’ll know how important it is to find the right care—and how overwhelming it can be to navigate the system. With the National Disab...

Online Medical Certificate Services: Essential Features to Look Out For

Hashtag.net.au - avatar Hashtag.net.au

"Discover top online medical certificate services! Essential features to look for to get trusted and efficient results." Choosing high-quality services is essential for ensuring reliable, efficient, ...